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Acquired drug resistance prevents cancer therapies from achieving stable and complete responses 1 . Emerging evidence implicates a key role for non-mutational drug resistance mechanisms underlying the survival of residual cancer 'persister' cells 2-4 . The persister cell pool constitutes a reservoir from which drug-resistant tumours may emerge. Targeting persister cells therefore presents a therapeutic opportunity to impede tumour relapse 5 . We previously found that cancer cells in a high mesenchymal therapy-resistant cell state are dependent on the lipid hydroperoxidase GPX4 for survival 6 . Here we show that a similar therapy-resistant cell state underlies the behaviour of persister cells derived from a wide range of cancers and drug treatments. Consequently, we demonstrate that persister cells acquire a dependency on GPX4. Loss of GPX4 function results in selective persister cell ferroptotic death in vitro and prevents tumour relapse in mice. These findings suggest that targeting of GPX4 may represent a therapeutic strategy to prevent acquired drug resistance.
We sought to identify therapeutically exploitable vulnerabilities in an experimental model of minimal residual disease, drug-tolerant persister cells. Persister cells, which are present across a wide range of tumour types, survive cytotoxic exposure to targeted therapy or chemotherapy through poorly understood, reversible, non-mutational mechanisms 2 . We focused our initial work on the HER2-amplified breast cancer line BT474, which, upon treatment for nine or more days with cytotoxic concentrations of lapatinib, reveals a small population of quiescent surviving persister cells (Fig. 1a ). Removal of lapatinib allows the persister cells to regrow and re-acquire sensitivity to lapatinib. Subsequent lapatinib treatment re-derives persister cells. The reversibility of drug resistance in BT474 persister cells, which is also observed in other persister cell models 2 including A375 melanoma (Extended Data Fig. 1a ), is indicative of a non-mutational resistance mechanism.
To identify cellular processes that may represent selective dependencies in persister cells, we performed RNA sequencing (RNA-seq) on BT474 persister cells and drug naive parental cells (Extended Data Tables 1, 2 and Supplementary Tables 1-4 ). In persister cells, we observed upregulation of stemness markers CD133 and CD44 consistent with earlier observations in other persister cell models 2 (Extended Data Table 1 ). We also observed upregulation of mesenchymal markers and downregulation of epithelial markers (Extended Data Table 1 ). This encouraged us to explore further the role that mesenchymal state biology may play in persister cell therapy resistance. In addition, a broad downregulation of antioxidant gene-expression in persister cells, including NRF2 target genes, directed our attention towards possible persister cell vulnerabilities in oxidative stress defence mechanisms (Extended Data Fig. 1b and Extended Data Table 2 ).
We recently reported that cancer cells in a high mesenchymal therapyresistant state are selectively sensitive to ferroptosis, an oxidative form of cell death that can be induced by inhibition of the lipid hydroperoxidase GPX4 6 . We included GPX4 inhibitors within a diverse collection of compounds screened against BT474 parental and persister cells, and found the GPX4 inhibitors RSL3 and ML210 to be among the compounds most selectively lethal to persister cells, with minimal effect on parental cells or non-transformed MCF10A cells (Fig. 1b, c and Extended Data Fig. 1c ). Given the observed phenotypic and gene-expression similarities between persister cells from different cancer types 2-4,7 , we wondered whether sensitivity to GPX4 inhibition might be a general persister cell vulnerability. Notably, we found that sensitivity to GPX4 inhibition extended beyond BT474 persister cells letter reSeArCH to a variety of other persister cell models ( Fig. 2a-h and Extended Data Fig. 1d ). In each case, we found the parental cells to be far less sensitive to GPX4 inhibitors ( Fig. 2a-h) . We also observed a less pronounced differential sensitivity of persister cells to the ferroptosis inducer erastin, which acts upstream of GPX4 by depleting the GPX4 cofactor glutathione 8 (Extended Data Fig. 1e , f).
We further confirmed the GPX4 dependency of persister cells using GPX4 knockout A375 melanoma cells ( Fig. 2i , j, Extended Data Fig. 1g and Supplementary Data). A hallmark of ferroptosis is the accumulation of lipid hydroperoxides, and lipophilic, small-molecule antioxidants have been shown to rescue cells from ferroptosis 9-11 . Upon withdrawal of the ferroptosis-rescuing lipophilic antioxidant ferrostatin-1, we observed that A375 GPX4-knockout, but not GPX4 wild-type, persister cells undergo ferroptotic death 6 ( Fig. 2i ). By contrast, the loss of GPX4 has minimal effect on parental A375 cell viability ( Fig. 2j ). Furthermore, we found that GPX4 inhibitors are not synergistic with lapatinib treatment of parental BT474 cells, demonstrating that GPX4 dependence is specific to the persister cell state (Extended Data Fig. 1h ). In addition, although p53 can regulate ferroptosis sensitivity 12 , we found that persister cells are dependent on GPX4 regardless of p53 status (Fig. 2) . These findings support the compelling hypothesis that GPX4 is a selective dependency of a drug-resistant persister cell state that is shared by cancer cells from many lineages subjected to diverse therapeutic regimens.
To test whether multiple persister cell types undergo canonical ferroptosis 10 upon GPX4 inhibition, we treated persister cells with a series of ferroptosis rescue compounds. We found that co-treatment with the lipophilic antioxidants ferrostatin-1 or liproxstatin-1 rescued various persister cell types from GPX4 inhibition ( Fig. 3a and Extended Data Fig. 2a-c) . Ferroptosis is an iron-dependent process, and although persister cells have less labile iron than parental cells (Extended Data Fig. 2d ), we observed that iron is nonetheless essential for GPX4 inhibitorinduced persister cell death, because iron chelation with deferoxamine partially rescues persister cells (Fig. 3b ). Consistent with the established role for lipoxygenase-catalysed lipid hydroperoxidation for ferroptosis, we observed that treatment with lipoxygenase inhibitors rescued persister cells from GPX4 inhibition ( Fig. 3c and Extended Data Fig. 2a, b ).
Lipid hydroperoxides must be transported by the lipid transporter SCP2 for cell death to occur 13, 14 . Accordingly, we found that persister cells were protected from GPX4 inhibition by chemical inhibition of SCP2 ( Fig. 3d and Extended Data Fig. 2a, b ). Also, in agreement with the non-apoptotic, caspase-independent nature of ferroptosis, we found that persister cell death from GPX4 inhibition is not rescued by the pan-caspase inhibitor Z-VAD-FMK ( Fig. 3e and Extended Data Fig. 2a -c). These ferroptosis characteristics were also observed in A375 GPX4-knockout persister cells upon removal of ferrostatin-1 ( Fig. 3f ). Taken together, these observations indicate that GPX4 inhibition induces canonical ferroptosis in persister cells.
On the basis of our observation that antioxidant genes are downregulated in persister cells (Extended Data Fig. 1b and Extended Data Table 2), we hypothesized that there may be a disabled antioxidant program that contributes to the sensitivity to ferroptosis. Glutathione and NADPH are two reducing cofactors that have been demonstrated to protect cells from the toxic effects of lipid peroxidation and prevent ferroptosis 10, 15, 16 . We found that persister cells have markedly decreased levels of both reducing cofactors (Fig. 4a, b and Extended Data Fig. 3a ). This is consistent with our observation that persister cells have downregulated expression of glutathione and NADPH biosynthesis genes (Extended Data Table 2 ). In addition, replacement of glutathione via treatment with the glutathione metabolic precursor N-acetyl cysteine partially rescues persister cells from ferroptosis (Extended Data Fig. 3b ). Persister cells have a specific sensitivity to lipid peroxidation, rather than general sensitivity to oxidative stress, because persister cells are not rescued from GPX4 inhibition by the antioxidants ebselen and EUK134 (Extended Data Fig. 3b ); exhibit only modestly increased sensitivity to endogenous reactive oxygen species (ROS) induced by DMNQ treatment (Extended Data Fig. 3c ); and are relatively insensitive to inhibition of an unrelated antioxidant enzyme, SOD1 (Extended Data Fig. 3d ). These findings indicate that global downregulation of NRF2 targets and other antioxidant genes, and decreased glutathione and NADPH act to impair persister cell lipid peroxidation defence and contribute to a dependence on GPX4.
Consistent with a disabled lipid peroxidation defence, we observed that after one hour of GPX4 inhibition and before any cell death, there letter reSeArCH is a marked increase in 2′ 7′ -dichlorofluorescein (DCF) staining of ROS, which indicates lipid peroxidation in persister cells but not parental cells ( Fig. 4c and Extended Data Fig. 3e ). Upon lipid hydroperoxide accumulation, free reduced glutathione levels are expected to decrease, because reduced glutathione covalently ligates, via glutathione-S-transferase catalysed or non-enzymatic glutathionylation, to oxidized products of lipid peroxidation, such as aldehydes 17 . Consistent with this, we observed a decrease in levels of reduced glutathione specifically in persister cells immediately after GPX4 inhibition that mirrored the increase in DCF staining ( Fig. 4a and Extended Data Fig. 3a ). Notably, a recent study found that persister cells are sensitive to the aldehyde dehydrogenase inhibitor disulfiram 3 . Although disulfiram was shown to cause apoptosis rather than ferroptosis, and is not rescued by ferrostatin-1 (Extended Data Fig. 3f ), the persister cell sensitivity to disulfiram may be more broadly reflective of the disabled antioxidant program.
We reasoned that an effective GPX4 inhibitor could potentially be used in a clinical setting to prevent tumour relapse. To test this possibility in a preclinical model, we developed an A375 melanoma xenograft model in which tumours respond and relapse upon treatment with dabrafenib and trametinib. Because neither RSL3 nor ML210 are systemically bioavailable, we instead adopted a recently developed genetic strategy 6 to test GPX4 dependence of residual tumours in vivo. We used GPX4-knockout or wild-type A375 cells (Extended Data Fig. 1g and Supplementary Data) to produce xenograft tumours in NCr nude mice. We then treated the mice with dabrafenib and trametinib to shrink the tumours while concurrently dosing the mice with ferrostatin-1 to mask any effects of GPX4 deletion before or during the initial response to drug treatment. Once tumours had been reduced to their minimal volume, ferrostatin-1 was withdrawn, unmasking the GPX4-knockout effect in these residual tumours. Upon further dosing of mice with dabrafenib and trametinib, without ferrostatin-1, the GPX4 wild-type tumours relapsed and the GPX4-knockout tumours did not ( Fig. 4d and Extended Data Fig. 3g ). By contrast, parental A375 GPX4-knockout and wild-type cells both formed tumours without ferrostatin-1 equally well (Extended Data Fig. 3h ). Taken together, these A375 melanoma xenograft data are consistent with an essential role for GPX4 in residual A375 tumours in vivo.
Our data reveal that co-treatment of cancer cells with a targeted therapy or chemotherapy agent together with a GPX4 inhibitor effectively reduces the residual persister cell pool. However, co-treatment with multiple drugs often results in increased toxic side effects that can compromise patient safety and treatment efficacy. Interestingly, we found that pretreatment of BT474 parental cells with RSL3 alone for 24 hours decreases the number of persister cells remaining after subsequent lapatinib treatment ( Fig. 4e ). This finding is consistent with recent reports that demonstrate that persister cells may pre-exist before drug treatment 3, 18 . We also observed that BT474 persister cells allowed to regrow after washout of lapatinib retain their full sensitivity to RSL3 for at least two weeks but for less than two months ( Fig. 4e and Extended Data Fig. 3i ), indicating that the impaired antioxidant program in persister cells is not immediately repaired upon drug removal and regrowth. These findings demonstrate that pre-or post-treatment with GPX4 inhibitors, rather than co-treatment, may be adequate to deplete the pool of persister cells that survive targeted therapy or chemotherapy. This staggered treatment strategy may be clinically beneficial in maximizing efficacy while minimizing the potential increase in toxicity that might be anticipated from simultaneous co-treatment with two agents.
Non-mutationally drug-tolerant persister cells have recently gained attention for their potential role in acquired drug resistance in which they may constitute a reservoir of surviving cells from which fully drug-resistant cells eventually emerge to cause tumour relapse 2,4,5 .
Here we have shown that GPX4 inhibition is a promising strategy to selectively eradicate this residual cell reservoir (Extended Data Fig. 3j ). Although existing GPX4 inhibitors, such as RSL3 and ML210, are valuable tool compounds in cell culture settings, their poor pharmacokinetic properties preclude their systemic use in vivo. Given the therapeutic promise for inducing ferroptosis in persister cells and drug-resistant cancers 6,19 , the development of a potent bioavailable GPX4 inhibitor is an urgent priority. Because GPX4 genetic deletion levels in BT474 cells treated with RSL3 for 1 h. c, ROS levels, as measured by DCF staining, in BT474 cells treated with RSL3 for 1 h. d, Relapse of A375 GPX4 wild-type or knockout (clone 1) tumours. Mice bearing GPX4 wild-type and knockout tumours on opposing flanks dosed with ferrostatin-1 were treated with dabrafenib and trametinib to shrink tumours to their minimal size. Ferrostatin-1 was then withdrawn and tumour relapse was monitored. See Source Data for individual data points. e, Fractional viability after 24-h RSL3 pretreatment of BT474 cells before derivation of persister cells (left), RSL3 treatment of cells regrown from persister cells upon lapatinib removal for 15 days (middle), or 2 months (right). Data are means and s.d., from three (a, e left and middle) or two (b, c, e right) biologically independent samples, and four animals (d). * P < 0.05; * * P < 0.01; * * * P < 0.001; * * * * P < 0.0001; NS, not significant (P > 0.05); two-tailed t-tests. All data are representative of two separate experiments.
letter reSeArCH is lethal in adult mice 13, 20 , further studies will be needed to determine whether a suitable therapeutic window exists for treatment with GPX4 inhibitors. In summary, we have found that GPX4 inhibition results in ferroptotic death in cancer persister cells across many lineages, presenting a novel strategy to prevent tumour relapse.
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Cell culture. HER2-amplified breast cancer BT474 (ATCC), EGFR-mutant nonsmall-cell lung cancer PC9 (Sigma-Aldrich) and Kuramochi ovarian cancer (JCRB) cells were cultured in RPMI-1640 medium, and BRAF-mutant A375 melanoma (ATCC) cells were cultured in DMEM, each supplemented with penicillin, streptomycin and 10% FBS. A375 GPX4-knockout cells were cultured in the presence of 2 μ M ferrostatin-1 unless otherwise noted. MCF10A (ATCC) cells were cultured in Mammary Epithelial Cell Growth Medium supplemented with bovine pituitary extract, gentamycin, amphotericin B (Lonza MEGM BulletKit), and 100 ng ml −1 cholera toxin (Sigma). Each cell line was maintained in a 5% CO 2 atmosphere at 37 °C. Cell line identities were confirmed by STR fingerprinting and all were found to be negative for mycoplasma using the MycoAlert kit (Lonza). Persister cell derivation and treatments. Persister cells were derived from treatment of HER2-amplified breast cancer BT474, EGFR-mutant non-small-cell lung cancer PC9 or Kuramochi ovarian cancer cells with 2 μ M lapatinib, 2 μ M erlotinib, or co-treatment with 10 μ M carboplatin and 100 nM paclitaxel, respectively, for at least 9 days with fresh drug added every 3 days. A375 persister cells were derived from 9 or more days of treatment with 2 μ M vemurafenib (Fig. 2i) , 25 μ M vemurafenib (Extended Data Fig. 1a ), 1 μ M dabrafenib and 100 nM trametinib ( Fig. 3f and Extended Data Fig. 2a, b ), or 2 μ M dabrafenib and 200 nM trametinib (Fig. 2b, f) . A375 GPX4-knockout cells were maintained in medium with 2 μ M ferrostatin-1 during persister cell derivation with drug. Chemotherapy-derived BT474 persister cells were similarly derived from co-treatment with 25 μ M carboplatin and 1.25 nM paclitaxel (Extended Data Fig. 1d ). Unless otherwise noted, small-molecule inhibitors were added to pre-derived persister cells in 12-well tissue culture plates that were maintained under constant drug exposure throughout subsequent smallmolecule inhibitor treatment. Cell viability was assessed using CellTiter Glo (Promega) after 3 days of small-molecule treatment, or 3 days after ferrostatin-1 removal in the case of A375 GPX4 knockout cell experiments, unless otherwise noted.
For testing RSL3 pretreatment before persister cell derivation and RSL3 treatment on cells regrown from persister cells (Fig. 4e) , the following experimental setup was used. In Fig. 4e (left) , BT474 parental cells were pretreated for 24 h with 1 μ M RSL3 alone, then RSL3 was removed and persister cells were subsequently derived from two weeks of treatment with 2 μ M lapatinib alone followed by a cell viability assay. For Fig. 4e (middle and right) , pre-derived BT474 persister cells from 2 μ M lapatinib were allowed to regrow upon removal of lapatinib for 15 days (middle) or 63 days (right) and were then treated for 3 days with 1 μ M RSL3 alone followed by a cell viability assay. Chemicals. (Z)-4-hydroxytamoxifen, altretamine, baicalein, BWA4C, deferoxamine mesylate salt, erlotinib hydrochloride, ferrostatin-1, gossypol, HA14-1, hydroxychloroquine, liproxstatin-1, ML210, PBIT, salinomycin, trigonelline hydrochloride, tunicamycin, zileuton and Z-VAD-FMK were purchased from Sigma-Aldrich. ABT-263, ABT-737, dabrafenib, paclitaxel, canertinib, fluvastatin, GSK2110183, GX15-070, LBH589, (1S,3R)-RSL3 (RSL3), romidepsin, saracatinib, trametinib, trichostatin A, TW-37 and vorinostat were purchased from Selleck Chemical. Mifepristone, pladienolide B, SB-431542, vemurafenib and XAV939 were purchased from Santa Cruz Biotechnology. Compound A (Mirk inhibitor), erastin, MIM1 and SP600125 were purchased from EMD Millipore. SCPI-2 and SCPI-4 were purchased from ChemBridge. Metformin and PD146176 were purchased from Enzo Life Sciences. AEW541 and JQ1 were purchased from Cayman Chemical. WEHI-539 was purchased from MedChem Express. Everolimus was purchased from Cell Signaling Technology. 17-DMAG was purchased from Biotang USA. Herboxidiene was purchased from Apollo Scientific. Sorafenib tosylate was purchased from AK Scientific. Spliceostatin A was purchased from AdooQ Bioscience. Lapatinib ditosylate was purchased from LC Laboratories. Nordihydroguaiaretic acid (NDGA) was purchased from Acros Organics. Carboplatin was purchased from Hospira or Sigma. All chemicals were stored as stock solutions in DMSO (Sigma-Aldrich) or nuclease-free water (Life Technologies). RNA-seq library preparation. To generate BT474 persister cells for RNA-seq, BT474 cells were plated in five 15-cm tissue culture plates per replicate, for three replicates, and were allowed to reach 75% confluency before being treated with 2 μ M lapatinib for nine days. Simultaneously, parental BT474 cells were cultured for nine days in lapatinib-free medium in two replicate 15-cm tissue culture plates. Approximately 2 million persister or parental cells were used per replicate for RNA isolation. RNA was isolated using Trizol (Life Technologies), following the manufacturer's instructions. RNA samples were quantified using a NanoDrop (ThermoFisher), and RNA integrity was determined using a RNA 6000 Nano Kit (Agilent) on an Agilent 2100 Bioanalyzer. All RNA samples had a measured RNA integrity number (RIN) greater than 9.3. RNA samples were sent to the UC Davis Genome Center for non-strand specific polyA enrichment, Illumina library preparation including multiplex barcodes and RNA-seq across six lanes of an Illumina HiSeq 2000 instrument. 145 million to 160 million single-end, 50-base-pair reads were obtained per replicate. RNA-seq data analysis. Fastq sequence files were aligned to hg18 using TopHat v.2.0.6, allowing only uniquely mapped reads with the '-g 1' option. Differential expression testing and assignment of FPKM and fold change values to genes was performed with CuffDiff v.2.0.2, comparing the two BT474 parental cell replicates to the three BT474 persister cell replicates. For CuffDiff, quartile normalization and '-compatible-hits-norm' options were used to assign reads to a GTF file containing all human RefSeq NM and NR genes which was downloaded from the UCSC Genome Browser and converted into a CuffDiff readable format using Cuffcompare as described in the Cufflinks manual.
The set of genes with minimum fragments per kilobase of transcript per million (FPKM) mapped reads greater than 1 in either parental cells or persister cells, greater than twofold upregulation or downregulation in persister cells relative to parental cells, and significant false discovery rate corrected P value (q < 0.05) as calculated by CuffDiff were used for core analysis with Ingenuity Pathway Analysis (IPA) software to generate IPA results for canonical pathways, upstream regulators, and functions ( Supplementary Tables 2-4 ). Analysis of differential expression among genes within previously established panels of mesenchymal and epithelial marker genes 21 (Extended Data Table 1) and human antioxidant genes 22 (Extended Data Fig. 1b and Extended Data Table 2 ) was also performed using FPKMs and fold changes calculated by CuffDiff. Chemical inhibitor screens. BT474 cells were seeded in duplicate 12-well tissue culture plates and were allowed to reach 75% confluency. To derive persister cells, each well was treated with 2 μ M lapatinib for 9 days, with fresh media containing 2 μ M lapatinib added every 3 days. Small-molecule inhibitors at 1 μ M concentration were then added in lapatinib-containing media and, after five days of incubation, each well was measured using CellTiter Glo reagent. CellTiter Glo measurements were made by transferring 200 μ l of the CellTiter Glo solution per well into Costar 96-well clear flat bottom plates for readout using a Promega GloMax Explorer luminometer. The CellTiter Glo luminescent signal was normalized to negative control wells by calculating the ratio of luminescence signal in the test versus negative control wells. Negative control wells contained media with 2 μ M lapatinib but no additional chemical inhibitors. Each small-molecule inhibitor was also tested at 1 μ M concentration in parental BT474 cells in 12-well plates, in which cells were seeded in duplicate wells at 25% confluency and treated with chemical inhibitors. After incubation for 5 days, cell viability was measured with CellTiter Glo. CRISPR-mediated GPX4 deletion. Guide RNAs targeting the first exon of human GPX4 were designed using the CRISPR Design tool (F. Zhang laboratory, MIT). pX330 (F. Zhang laboratory, MIT) expression plasmids encoding the single-guide RNAs 5′ -CACGCCCGATACGCTGAGTG-3′ (for GPX4 knockout clone 1) or 5′ -CTTGGCGGAAAACTCGTGCA-3′ (for GPX4 knockout clone 2) and Streptococcus pyogenes Cas9 were generated and transfected into A375 cells in the presence of 2 μ M ferrostatin-1 using Lipofectamine 3000 (Life Technologies). The cells were subjected to two rounds of transfection. In the first round, the CRISPR plasmids were co-transfected with a vector encoding mCherry and puromycin resistance. Then, 24 h after the transfection, the cells were selected with 1 μ g ml −1 puromycin for 3 days. The selected cells were expanded and transfected again with the pX330 CRISPR constructs and a pMax-GFP reporter. 24 h after the transfection, the cells were sorted and the GFP-positive, mCherry-negative cells were retained. Cells were then transferred into 96-well plates at ~ 1 cell per well and expanded as clones. Genomic DNA was extracted from all clones with the NucleoSpin Blood kit (Macherey-Nagel). The GPX4 target sites were amplified from 100 ng of genomic DNA with Phusion DNA Polymerase (NEB) with primers forward 5′ -GTAAAACCGGACCAGAAGTACAAG-3′ and reverse 5′ -CCCACCTGCTTCCCGAACTG-3′ . Purified PCR products were TOPO cloned (Life Technologies) and sequenced with primer M13F (Quintara). 5 TOPO colonies from each clone were sequenced to confirm frameshifts in GPX4.
A375 GPX4 knockout clones 1 and 2 were confirmed to lack GPX4 protein by western blot. For this, 3 million cells were seeded in 10-cm tissue culture plates and grown to 75% confluence, and the next day, cells were trypsinized, washed with PBS, and lysed using RIPA buffer (Thermo Scientific) supplemented with phosphatase inhibitor (Sigma) and protease inhibitor (Sigma). Lysates were centrifuged at 10,000g at 4 °C for 12 min, and the protein concentration of the supernatant was determined using the Bio-Rad Protein Assay. 40 μ g of protein per sample was mixed with sample buffer (Bio-Rad) and denatured at 95 °C for 5 min. Samples were separated by SDS-PAGE (NuPage 4-12% Bis-Tris Gel, Life Technologies), run with BioRad Precision Plus Protein Kaleidoscope ladder, and transferred to a nitrocellulose membrane using an iBlot system (Life Technologies). Membranes were blocked with 5% BSA for 1 h at room temperature, and then incubated with either a 1:1,000 dilution of anti-GPX4 (rabbit) polyclonal antibody (Abcam, ab41787) or 1:5,000 dilution of anti-β -actin (mouse) monoclonal antibody (Sigma, A5441) at 4 °C overnight. LICOR secondary antibodies were then incubated with the letter reSeArCH membrane for 1 h at room temperature, and the membrane was imaged using the LICOR Odyssey Imaging System. Glutathione and NADPH measurements. NADP/NADPH-Glo and GSH-Glo assay kits (Promega) were used to measure NADPH levels in 20,000 cells and glutathione levels in 50,000 cells per replicate following manufacturer's instructions. To measure total glutathione (GSH + GSSG), oxidized glutathione (GSSG) was reduced by incubating test samples with 500 μ M tris(2-carboxyethyl)phosphine (TCEP) for 10 min before luminescence measurement, following the manufacturer's instructions. Each assay was read out using a Promega GloMax Explorer luminometer. Intracellular reactive oxygen species measurements. BT474 cells plated in replicate 10-cm tissue culture plates were treated with 2 μ M lapatinib for at least 9 days, with fresh media added every 3 days, to derive persister cells. For cells re-grown from persister cells (Extended Data Fig. 3i ), lapatinib was subsequently removed from persister cells and fresh lapatinib-free media was replaced every 3 days for 15 days. Then, for both the persister cell experiments ( Fig. 4c and Extended Data Fig. 3e ) and regrown cell experiments (Extended Data Fig. 3i ), cells were treated with 1 μ M RSL3 or ML210 for 1 h. RSL3 or ML210 was removed and cells were trypsinized. For each replicate, 100,000 cells were pelleted and cell pellets were resuspended in full media containing 25 μ M 6-carboxy-2′ ,7′ -dichlorodihydrofluorescein diacetate, di(acetoxymethyl ester) (carboxy-DCFDA, acetoxymethyl ester) (Thermo Fisher Scientific) in HBSS with 1% FBS. After 30 min of incubation with DCF dye, cells were pelleted again, resuspended in HBSS with 1% FBS and green fluorescence was analysed with a SONY SH800S Cell Sorter. Because HER2-bound lapatinib is green fluorescent 23 , data for persister cells were normalized to unstained persister cells, and parental cell data were normalized to unstained parental cells. A minimum of 3,000 cells were analysed for each persister and parental replicate. Data were processed with FloJo software. Iron measurements. Total labile iron (Fe(ii) and Fe(iii) combined) was measured using the colourimetric Iron Assay Kit (Abcam) following the manufacturer's instructions. In total 1.4 million BT474 persister or parental cells were tested per replicate for two biological replicate samples. Colourimetric signal was read out using a BioTek Synergy 2 Microplate Reader. Xenograft experiments. The University of California San Francisco Institutional Animal Care and Use Committee (IACUC) approved the xenograft studies in Protocol #AN142193. Tumour size criteria permitted a maximum volume of 2,000 mm 3 , however, careful observation of the animals and body condition score of two or less superseded any laboratory measurement. These limits were not exceeded in any experiments. For the formation of xenograft tumours without ferrostatin-1 (Extended Data Fig. 3h ), 10 million A375 GPX4 wild-type or GPX4 knockout (clone 1) cells were mixed in a 1:1 PBS:Matrigel mixture and injected into the left or right flanks, respectively, of female athymic mice aged 10-12 weeks with a mean body weight of 24 g (NCr Nude, Taconic). Tumour volume measurements were made twice a week. All mice were included in the analysis. For the tumour relapse experiments ( Fig. 4d and Extended Data Fig. 3g ), 10 million A375 GPX4 wild-type or knockout (clone 1) cells were mixed in a 1:1 PBS:Matrigel mixture containing 2.5 μ M ferrostatin-1 and injected into left and right flanks, respectively, of male athymic NCr nude mice aged 10-12 weeks with a mean body weight of 25 g. Mice were dosed daily intraperitoneally with 0.2 mg kg −1 ferrostatin-1 while tumours were initially established and during subsequent treatment with 100 mg kg −1 dabrafenib and 1 mg kg −1 trametinib twice daily by oral gavage. Once tumours had shrunk and tumour volumes had stabilized, ferrostatin-1 treatment was ceased while dabrafenib and trametinib treatment was continued and tumours relapsed. All mice for which any tumour relapsed were included in the analysis. 
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Experimental design 1. Sample size
Describe how sample size was determined.
For mouse experiments, no statistical methods were used to predetermine sample size.
Data exclusions
Describe any data exclusions.
No data were excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
All experiments were performed in two or three biological replicates, and independently reproduced as indicated in figure legends.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
For mouse experiments, the mice were not randomized.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
For mouse experiments, the investigators performing tumour volume measurements were blinded.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
